Ascentage Pharma Group International
06855
Company Profile
Business description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.
Contact
68 Xinqing Road
Suzhou Industrial Park
Jiangsu
Suzhou215000
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
767
Stocks News & Analysis
stocks
US utilities stocks keep rallying as investors bet on power demand growth
Rising electricity demand from data centers supports earnings growth, but Morningstar analysts say the sector looks less attractive after a sharp rally.
stocks
What did Morningstar subscribers buy and sell during March?
How the most traded shares in March stack up against our analysts views.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.10 | 29.30 | -0.32% |
| CAC 40 | 8,235.98 | 23.62 | -0.29% |
| DAX 40 | 23,742.44 | 61.51 | -0.26% |
| Dow JONES (US) | 48,218.25 | 301.68 | 0.63% |
| FTSE 100 | 10,582.96 | 17.57 | -0.17% |
| HKSE | 25,757.87 | 97.02 | 0.38% |
| NASDAQ | 23,183.74 | 280.84 | 1.23% |
| Nikkei 225 | 57,805.60 | 1,302.83 | 2.31% |
| NZX 50 Index | 13,017.26 | 2.92 | -0.02% |
| S&P 500 | 6,886.24 | 69.35 | 1.02% |
| S&P/ASX 200 | 8,983.30 | 30.70 | -0.34% |
| SSE Composite Index | 4,005.20 | 16.64 | 0.42% |